Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors

被引：0
|
作者：
Zhang, Songling
Zhu, Xiaoxue
Gao, Lei
Qi, Yaling
Jia, Xiao
Li, Yongguo
Guo, Ye
Ding, Yanhua
机构：
[1] First Hosp Jilin Univ, Gynecol & Obstet Ctr, Dept Gynecol Oncol, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China
[3] First Hosp Jilin Univ, Changchun, Peoples R China
[4] Shanghai Jiatan Pharmatech CO LTD, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14627
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase 1/2a Study of a PI3Kδγ. dual inhibitor ZX-101A in patients with advanced solid tumors
    Qin, Xiaoli
    Luo, Lori
    Li, Ying-ying
    Wang, Yin
    Sun, Shuaijun
    Hao, Xiaolin
    Yang, Jinfu
    CANCER RESEARCH, 2022, 82 (12)
  • [22] A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors
    Shu, Pei
    Li, Xiaoyu
    Yuan, Li
    Zhou, Qi
    Li, Guiling
    Zhang, Keqiang
    Xie, Hui
    Wang, Yongsheng
    Li, Qiu
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors
    Starks, David C.
    Rojas-Espaillat, Luis
    Meissner, Tobias
    Williams, Casey B.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 403 - 409
  • [24] A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    Johanna C. Bendell
    Carla Kurkjian
    Jeffrey R. Infante
    Todd M. Bauer
    Howard A. Burris
    F. Anthony Greco
    Kent C. Shih
    Dana S. Thompson
    Cassie M. Lane
    Lindsey H. Finney
    Suzanne F. Jones
    Investigational New Drugs, 2015, 33 : 463 - 471
  • [25] A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    Bendell, Johanna C.
    Kurkjian, Carla
    Infante, Jeffrey R.
    Bauer, Todd M.
    Burris, Howard A., III
    Greco, F. Anthony
    Shih, Kent C.
    Thompson, Dana S.
    Lane, Cassie M.
    Finney, Lindsey H.
    Jones, Suzanne F.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 463 - 471
  • [26] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 163 - 174
  • [27] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George, Jr.
    Richards, Donald
    Genvresse, Isabelle
    Reschke, Susanne
    Granvil, Camille
    Skubala, Adam
    Pena, Carol
    Mross, Klaus
    TARGETED ONCOLOGY, 2020, 15 (02) : 163 - 174
  • [28] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [29] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Eunice Kwak
    Susan Pandya
    Charles M. Rudin
    Carla Kurkjian
    James M. Cleary
    Mary Jo Pilat
    Suzanne Jones
    Alex de Crespigny
    Jill Fredrickson
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Hsin-Ju Hsieh
    Mary R. Gates
    Iris T. Chan
    Johanna Bendell
    Investigational New Drugs, 2020, 38 : 419 - 432
  • [30] A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.
    LoRusso, Patricia
    Shapiro, Geoffrey
    Pandya, Shuchi Sumant
    Kwak, Eunice Lee
    Jones, Cheryl
    Belvin, Marcia
    Musib, Luna C.
    de Crespigny, Alex
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris Tan-Chi
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345